Actually, it's the other way around. The treatment described is an adaption of CAR-T (Chimeric Antigen Receptor T-cell) therapy, which was approved for use in the United States in 2017, to the patient's specific form of leukemia. It's a challenging adaptation because the cancer cells being targeted are the same type of T-cells that are used in CAR-T therapy, thus requiring the use of donor T-cells, and a number of modifications that are unnecessary when CAR-T is used for other cancers. Base editing makes that easier than earlier forms of CRISPR. But base editing isn't the therapy here, CAR-T is, and while CAR-T is certainly relatively, this patient is not the first to receive, just the first with her particular leukiemia.